secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059461
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Q3 net loss narrows; exa-cel PDUFA: Dec 8 (SCD) & Mar 30, 2024 (TDT)
---------------------------------------------------------------------------

- PDUFA target action date for exa-cel in sickle cell disease: Dec 8, 2023; for beta thalassemia: March 30, 2024.
- Net loss narrowed to $112.2M in Q3 2023 from $174.5M in Q3 2022; cash $1.74B.
- R&D expenses decreased to $90.7M from $116.6M; G&A down to $18.3M from $27.0M.
- Initiated Phase 1 trial for CTX310 targeting ANGPTL3; CTX320 on track for clinic in H1 2024.
- Proposed election of Sandy Mahatme to Board at 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/0000950170-23-059461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023059461/crsp-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer